Welcome, Guest. Please login or register.
December 12, 2024, 03:40:51 am

Login with username, password and session length


Members
  • Total Members: 6315
  • Latest: DRG
Stats
  • Total Posts: 55135
  • Total Topics: 4853
  • Online Today: 246
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 230
Total: 230

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Study Finds African Americans Shouldn’t Be Excluded From 8-Weeks of Harvoni  (Read 5654 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
A new study contradicts current guidelines that stipulate that African Americans who qualify for a shortened eight-week course of Harvoni (ledipasvir/sofosbuvir) treatment for hepatitis C virus (HCV) should nevertheless receive 12 weeks, reports MedPage Today.

According to an observational study of a real-world cohort, Blacks who otherwise met the guidelines of the American Association of the Study of Liver Diseases and of the Infectious Diseases Society of America for taking eight weeks of the regimen had a cure rate comparable to their peers who were treated for 12 weeks.

Read more...
https://www.hepmag.com/article/study-finds-african-americans-excluded-8weeks-harvoni

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.